Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 20

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 program, the time to complete the program development, and overall biotech indices. The Company determined the fair value of the contingent consideration was $10.5 million as of March 31, 2025 and the increase of $0.3 million from December 31, 2024 has been recorded as a component of total operating expenses in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025. The assumptions used in the discounted cash flow model are level 3 inputs as defined above. There were no changes in the assumptions as of March 31, 2025 compared to December 31, 2024. The Company assessed the sensitivity of the fair value measurement to changes in these unobservable inputs, and determined that changes within a reasonable range would not result in a materially different assessment of fair value.  

 8

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:Level 1Level 2Level 3TotalAs of March 31, 2025(in thousands)AssetsCash and cash equivalents$37,076 $— $— $37,076 Investments in marketable securities, current— 75,631 — 75,631 Total$37,076 $75,631 $— $112,707 LiabilitiesContingent consideration— — 10,524 10,524 Total$— $— $10,524 $10,524 Level 1Level 2Level 3TotalAs of December 31, 2024(in thousands)AssetsCash and cash equivalents$36,330 $— $— $36,330 Investments in marketable securities, current— 86,293 — 86,293 Total$36,330 $86,293 $— $122,623 LiabilitiesContingent consideration— — 10,225 10,225 Total$— $— $10,225 $10,225 The following table presents the changes in fair value of the Company’s contingent consideration:  Liability at beginning of the periodChange in fair value of liabilityLiability at end of the period(in thousands)Three Months Ended March 31, 2025$10,225 $299 $